pluristem therapeutics inc (PSTI) Key Developments
Pluristem Therapeutics, Inc. Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial
Jul 8 14
Pluristem Therapeutics Inc. announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). Patient screening is now underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II trial. The trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients. In May 2014, Pluristem received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) to use PLX cells in South Korean trials.
Pluristem Therapeutics, Inc. Presents at Barclays Select Series 2014: Israel Biotech/Medtech Corporate Day, May-29-2014
May 27 14
Pluristem Therapeutics, Inc. Presents at Barclays Select Series 2014: Israel Biotech/Medtech Corporate Day, May-29-2014 . Venue: 745 Seventh Avenue, New York, New York, United States. Speakers: Karine Kleinhaus, Divisional Vice President of North- America.
Pluristem Therapeutics Inc. Announces Amendment to the Amended and Restated Articles of Incorporation
May 22 14
Pluristem Therapeutics Inc. at its annual meeting of stockholders on May 22, 2014, approved amendment to the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock.
Pluristem Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 03:30 PM
May 21 14
Pluristem Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 03:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Karine Kleinhaus, Divisional Vice President of North- America, Zami Aberman, Executive Chairman and Chief Executive Officer.
Pluristem Receives Clearance from South Korea to Use PLX Cells Manufactured at its New Facility in its Advances Studies
May 20 14
Pluristem Therapeutics, Inc. announced the latest advancement in its clinical and commercial development programs in South Korea. The South Korean Ministry of Food and Drug Safety has recently cleared Pluristem's upgraded manufacturing process in its new facility in Haifa, Israel. The cells produced at Pluristem new facility will be used by Korean sites joining the large Phase II study currently conducted by Pluristem in intermittent claudication (IC) patients. This Phase II IC study is currently ongoing in the U.S., Israel and Germany. Under the terms of the agreement, CHA will perform and fund multiple clinical trials in South Korea using Pluristem proprietary PLX cells. Upon the first regulatory approval for a PLX product in South Korea, Pluristem and CHA will establish a joint venture (JV) co-owned by the parties.